Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ZIOP

ZIOPHARM Oncology (ZIOP) Stock Price, News & Analysis

ZIOPHARM Oncology logo

About ZIOPHARM Oncology Stock (NASDAQ:ZIOP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.82
$1.39
52-Week Range
N/A
Volume
2.13 million shs
Average Volume
2.01 million shs
Market Capitalization
$187.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Receive ZIOP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.

ZIOP Stock News Headlines

Best Global Universities for Oncology
Is he more powerful than Trump?
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Alx Oncology Holdings (ALXO)
CG Oncology Inc
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
WBSPH 2024 - Oncology
See More Headlines

ZIOP Stock Analysis - Frequently Asked Questions

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced its earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. The biotechnology company had revenue of $0.40 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that ZIOPHARM Oncology investors own include Precigen (PGEN), Bristol-Myers Squibb (BMY), OPKO Health (OPK), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Amarin (AMRN) and CorMedix (CRMD).

Company Calendar

Last Earnings
11/08/2021
Today
5/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZIOP
Employees
105
Year Founded
2005

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-79,980,000.00
Pretax Margin
-22,544.97%

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.58 per share
Price / Book
N/A

Miscellaneous

Free Float
204,906,000
Market Cap
$187.12 million
Optionable
Optionable
Beta
1.71

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:ZIOP) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners